ADCs in Pharma Antibody Drug Conjugate Market Revolution
Although antibody-drug conjugates (ADCs) have been available for over a decade, recent momentum is surging—with six of twelve FDA approvals since 2020, including billion-dollar acquisitions by major pharma companies in late 2023 and early 2024. For more info: https://www.zs.com/insights/oncology-antibody-drug-conjugates-revolution
Although antibody-drug conjugates (ADCs) have been available for over a decade, recent momentum is surging—with six of twelve FDA approvals since 2020, including billion-dollar acquisitions by major pharma companies in late 2023 and early 2024. For more info: https://www.zs.com/insights/oncology-antibody-drug-conjugates-revolution
ADCs in Pharma Antibody Drug Conjugate Market Revolution
Although antibody-drug conjugates (ADCs) have been available for over a decade, recent momentum is surging—with six of twelve FDA approvals since 2020, including billion-dollar acquisitions by major pharma companies in late 2023 and early 2024. For more info: https://www.zs.com/insights/oncology-antibody-drug-conjugates-revolution
0 Commentaires
0 Parts
9 Vue
0 Aperçu
English
Arabic
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek
